Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noisy Rebels: rituximab versus ocrelizumab in relapsing multiple sclerosis
NL-OMON58724Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of rituximab and ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: No new or enlarged T2 brain MRI lesions from month 6 to month 24. Started May 2023; status: active, not recruiting.
02
Drugs
rituximabocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON58724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58724.